ALX Oncology Holdings Inc (ALXO)
1.67
-0.05
(-2.91%)
USD |
NASDAQ |
Oct 04, 16:00
1.69
+0.02
(+1.20%)
After-Hours: 20:00
ALX Oncology Holdings Shareholders Equity (Annual): 189.71M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 189.71M |
| December 31, 2022 | 263.46M |
| December 31, 2021 | 363.05M |
| Date | Value |
|---|---|
| December 31, 2020 | 429.84M |
| December 31, 2019 | -0.276M |
| December 31, 2018 | 9.155M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
-0.276M
Minimum
2019
429.84M
Maximum
2020
249.16M
Average
263.46M
Median
2022
Shareholders Equity (Annual) Benchmarks
| Biomarin Pharmaceutical Inc | 4.952B |
| IDEAYA Biosciences Inc | 621.09M |
| Immunovant Inc | 617.76M |
| Verve Therapeutics Inc | 599.50M |
| Immuneering Corp | 90.58M |